Juniper Pharma (Formerly known as Columbia Laboratories)
4 Liberty Square
Boston
Massachusetts
02109
United States
Tel: 617-639-1500
Website: http://www.juniperpharma.com/
Email: enquiry@juniperpharma.com
274 articles about Juniper Pharma (Formerly known as Columbia Laboratories)
-
BioSpace Movers and Shakers Nov. 5
11/5/2018
Biopharma companies make key appointments to fill leadership positions. Let's take a look! -
Catalent Completes Tender Offer for All Outstanding Shares of Juniper Pharmaceuticals, Inc.
8/14/2018
Catalent, Inc. announced the successful completion of the previously announced tender offer by Catalent Boston, Inc.
-
Juniper Pharmaceuticals Reports Second Quarter 2018 Financial and Operating Results
8/9/2018
Signs Agreement to be Acquired by Catalent, Inc.
-
CORRECTING and REPLACING Catalent Signs Agreement to Acquire Juniper Pharmaceuticals, Inc.
7/8/2018
$133 Million Deal Adds European Early Development Center of Excellence to Global Network CORRECTION...by Catalent, Inc.
-
Shares of Juniper Pharmaceuticals have soared more than 31 percent in premarket trading after the company announced it will be acquired by drug delivery company Catalent, Inc. in a deal with a total equity value of approximately $139.6 million.
-
Catalent Signs Agreement to Acquire Juniper Pharmaceuticals, Inc.
7/3/2018
$133 Million Deal Adds European Early Development Center of Excellence to Global Network.
-
Juniper Pharmaceuticals Reports First Quarter 2018 Financial and Operating Results
5/10/2018
Core Businesses Driving Strong Financial Performance CRINONE® Revenues Increased 30% and Juniper Pharma Services (JPS) Revenues Increased 55% Year-over-Year Conference Call at 8:30 a.m. EDT Today
-
Juniper Pharmaceuticals to Report First Quarter 2018 Results on May 10, 2018
5/1/2018
Juniper Pharmaceuticals will hold a conference call on May 10, 2018, to discuss the financial results for the first quarter ended March 31, 2018.
-
Juniper Pharmaceuticals Licenses Intravaginal Ring (IVR) Platform to Daré Bioscience
4/25/2018
Juniper Pharmaceuticals, Inc. announced an exclusive worldwide license agreement with Daré Bioscience for the development and commercialization of the Company's intravaginal ring (IVR) technology platform.
-
Juniper Pharmaceuticals Appoints Richard Messina to Board of Directors
3/21/2018
Juniper Pharmaceuticals, Inc. (Nasdaq: JNP), a diversified healthcare company with core businesses of its CRINONE® (progesterone gel) franchise and fee-for-service pharmaceutical development and manufacturing business JPS, today announced the appointment of Richard Messina to the Company's Board of Directors.
-
Juniper Pharmaceuticals Reports Full-Year 2017 Financial and Operating Results
3/8/2018
Full Year CRINONE® Revenues Increased 20% and Juniper Pharma Services (JPS) Revenues Increased 32% Year-over-Year Ended 2017 Cash Flow Positive; Company Expects Trend to Continue in 2018 Conference Call at 8:30 a.m. EST Today
-
Juniper Pharmaceuticals to Explore Strategic Alternatives
1/31/2018
The Company has engaged Rothschild as its independent financial advisor to assist Juniper and its Board of Directors in evaluating potential strategic alternatives.
-
Juniper Pharma Announces 4.5-Year Extension Through 2024 of CRINONE® Supply Agreement with Merck KGaA, Darmstadt, Germany
1/8/2018
Juniper Pharma today announced the extension of its supply agreement for CRINONE with an affiliate of Merck KGaA, Darmstadt, Germany.
-
Juniper Pharma Outlines Strategic Priorities for 2018 and Reports Recent Portfolio Progress
1/3/2018
Juniper Pharma today provided financial guidance for 2018, reflecting continued strength in the Company's core businesses, JPS and CRINONE, and provided an overview of strategic priorities for 2018.
-
Juniper Pharmaceuticals Reports Third Quarter 2017 Financial and Operating Results
11/3/2017
Cash and cash equivalents were $22.1M at September 30, 2017, an increase of 3% from June 30, 2017.
-
Juniper Pharmaceuticals to Report Third Quarter 2017 Results on November 2, 2017
10/27/2017
Juniper Pharma, will hold a conference call on November 2, 2017, to discuss the financial results for the third quarter ended September 30, 2017.
-
Juniper Pharma Appoints Jennifer Good To Board Of Directors
9/12/2017
-
Juniper Pharma Reports Second Quarter 2017 Financial And Operating Results
8/4/2017
-
Juniper Pharma To Report Second Quarter 2017 Results On August 3, 2017
7/28/2017
-
Juniper Pharma Announces Results Of 2017 Annual Meeting
7/6/2017